Quince Therapeutics, Inc. (QNCX) – What Are Researchers Thinking About This Stock?

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $189.88.

QNCX has been the topic of a number of research analyst reports. Zacks Research upgraded Quince Therapeutics to a “hold” rating in a report on Thursday, October 1st. Citizens Jmp upgraded Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 price target for the company in a research note on Tuesday, September 22nd. Wall Street Zen lowered Quince Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Oppenheimer assumed coverage on Quince Therapeutics in a report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price objective on the stock. Finally, Rodman & Renshaw assumed coverage on Quince Therapeutics in a research note on Thursday, September 24th. They issued a “buy” rating and a $70.00 price objective on the stock.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $31.73 on Wednesday. The company has a market cap of $32.27 million, a P/E ratio of -0.20 and a beta of 1.33. Quince Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $909.98. The firm’s 50 day moving average is $30.93 and its two-hundred day moving average is $25.31.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($28.02) by $15.71. Research analysts forecast that Quince Therapeutics will post -8.39 earnings per share for the current fiscal year.

Institutional Trading of Quince Therapeutics

An institutional investor recently bought a new position in Quince Therapeutics stock. BlackRock Inc. purchased a new stake in Quince Therapeutics, Inc. (NASDAQ:QNCX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,702 shares of the company’s stock, valued at approximately $31,000. BlackRock Inc. owned 0.17% of Quince Therapeutics as of its most recent filing with the Securities & Exchange Commission. 30.75% of the stock is owned by hedge funds and other institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc (NASDAQ:QNCX) is a clinical-stage biotechnology company developing therapies for rare and debilitating diseases. The company focuses on precision medicines designed to address underlying disease mechanisms and unmet medical needs in patient populations that may have limited treatment options.

Quince’s pipeline includes efzofitimod, an investigational immunomodulator being developed for pulmonary sarcoidosis, a rare inflammatory disease that can affect lung function.